VIANEX Group invests in iDNA Genomics & iDNA Laboratories

An agreement was announced on the participation of the VIANEX Group in the equity capital of iDNA. Extension of VIANEX Group products and services for the benefit of patients with innovative solutions. The VIANEX Group proceeds to a strategic partnership with the 2 Greek genetic companies iDNA Genomics and iDNA Laboratories, at a medical and commercial level respectively, which are active in the field of Medical Accuracy and Genomic Analysis (DNA Test) with a view to personalized health care. Through this collaboration, the VIANEX Group, participating in the equity capital of iDNA, expands its activity in the area of prevention and promotes innovation in the field of health through products that have been identified as pioneering and help both prevent serious diseases such as cardiovascular diseases, as well as the treatment of chronic diseases, such as depression and obesity. These are products which are the result of extensive research and development and have received international recognition as well as CE IVD certification. At the same time, the production process uses specialized scientific expertise in last generation laboratory equipment. VIANEX Group undertakes the promotion of genetic analyses at Greek and global level. Genetic analyses are aimed at health scientists aiming at individualization of clinical care through the control of genetic predispositions for diseases and response to medication. The power of knowledge and the evolution of science are for the VIANEX Group the driving force to expand and improve its services to health professionals for the benefit of patients. On the occasion of the investment, Dimitris Giannakopoulos, President & CEO of VIANEX, said: “In the VIANEX Group we travel our second century history and we are still in constant search for innovative solutions in the field of health and medicine. We are happy to expand our activity in the field of prevention by moving forward in cooperation with iDNA aiming to promote innovative and certified products that will facilitate health scientists in finding personalized treatment for the patient.” Accordingly, Fotis Sakellaridis founder and President of iDNA stated: “In iDNA we are excited about the collaboration with VIANEX Group. We have tried and managed as a company to create and certify in Europe products of high innovation and unique technology that can provide a cure solution for patients and prevent them from being healthy. This new strategic cooperation provides an excellent prospect for the development of a Greek company both in our country and in the global market. “